Eltrekibart

Eltrekibart is Eli Lilly's humanized antibody that neutralizes seven ELR+ CXC chemokines (CXCL1, 2, 3, 5, 6, 7, and 8), the family of signals that summon neutrophils to inflamed tissue. Lilly is running a Phase 2 combination trial (NCT06598943, n=143) with four arms - eltrekibart monotherapy, mirikizumab monotherapy, the combination, and placebo - in moderately-to-severely active ulcerative colitis, with primary completion in December 2027 [1]. The hypothesis: hit both the neutrophil arm and the T-cell arm of gut inflammation at once, and get remission rates that neither monotherapy delivers. Mirikizumab (Omvoh) is Lilly's own anti-IL-23p19 antibody, approved in the US in October 2023 for UC [5]. A separate Phase 2 in hidradenitis suppurativa (Forman et al., J Am Acad Dermatol Feb 2026, NCT04493502) missed its primary endpoint on the pre-specified in-trial comparison (HiSCR50 48.9% eltrekibart vs. 31.8% placebo, p=0.19) but hit a Bayesian augmented-control secondary analysis with 99.9% posterior probability of superiority (65.6% vs. 32.3%) [2][3]. That is a mixed first human efficacy read on the whole ELR+ chemokine mechanism, not the clean win the trial was designed to deliver.

Novel compound, no prior approvals anywhere. Only Eli Lilly is developing it, no partnerships disclosed. Active or recently reported trials as of mid-2026: NCT06598943 (Phase 2 UC, four-arm combo/monotherapy/placebo, recruiting, target n=143, primary completion December 2027) [1]; NCT04493502 (Phase 2 HS, completed; Forman et al. JAAD Feb 2026 reported a primary-endpoint miss with a positive Bayesian augmented-control secondary) [2][3]; NCT06046729 (a separate Phase 2 HS program registered under the same eltrekibart/LY3041658 identifier) [8]; and NCT07545590 (Phase 1 healthy volunteer PK study, n=60, active) [4]. No FDA breakthrough, fast track, orphan, or accelerated approval designations have been disclosed. The UC combination readout in 2027 is the near-term commercial catalyst. The published HS dataset is the first standalone human efficacy signal for the ELR+ CXC chemokine class in an inflammatory indication, and it is equivocal.

Chemokines are small proteins that act like breadcrumbs, guiding immune cells to inflamed tissue. The 'ELR+ CXC' family (named after a three-amino-acid Glu-Leu-Arg motif at the front of the molecule) consists of seven human ligands - CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, and CXCL8 (also known as IL-8) - all of which bind the neutrophil-surface receptors CXCR1 and CXCR2. When those receptors fire, neutrophils crawl out of blood vessels into tissue. In ulcerative colitis, neutrophils pile into the colon wall, release toxic enzymes and reactive oxygen species, and produce the crypt abscesses that define the disease under a microscope. The pharmacology bet is a family-wide block. Companies have tried anti-IL-8 (CXCL8) monoclonals for decades with limited efficacy because the other six ELR+ ligands take over the recruitment job. Eltrekibart binds all seven. That is different from blocking the receptor directly. Blocking the ligands rather than the receptor preserves partial CXCR1/2 receptor reserve - the receptor remains expressed and functional if unblocked ligands appear or if endogenous emergency signals bypass the neutralized ligand pool. Direct CXCR2 small-molecule antagonists (danirixin, AZD5069, navarixin, ladarixin) achieve complete receptor silence, which is likely one reason they showed dose-limiting neutropenia and infection signals in COPD, ARDS, and oncology trials and never delivered on hard outcomes. Mechanism validation for UC specifically: neutrophil-rich histology is a strong predictor of relapse and severity, and fecal calprotectin (a neutrophil-derived protein) is the standard biomarker for disease activity. What is not yet validated in humans: whether damping neutrophil recruitment translates to symptomatic remission rather than just prettier biopsies. That is the question the combo trial with mirikizumab has to answer.

NCT06598943 is a Phase 2 randomized, double-blind trial in adults with moderately-to-severely active ulcerative colitis, target enrollment 143, primary completion December 2027, study completion September 2028 [1]. Primary endpoint is percentage of participants achieving clinical remission (Mayo score criteria standard for this population). The registry lists four arms: eltrekibart + placebo, mirikizumab + placebo, eltrekibart + mirikizumab, and placebo - meaning the trial does include a mirikizumab-monotherapy comparator, which is essential to isolate any combination benefit. The combination hypothesis is clean on paper: mirikizumab blocks IL-23, which drives Th17-cell differentiation and downstream IL-17 production, damping the adaptive arm of gut inflammation; eltrekibart neutralizes the ELR+ chemokines that recruit neutrophils, damping the innate arm. Two upstream levers on two different immune cell populations. The trial's limitation is size. At n=143 spread across four arms, it is powered to detect a signal, not to definitively separate combination from mirikizumab monotherapy. A convincing readout still leaves Lilly with a two-year, multi-thousand-patient Phase 3 decision, and the delta over Omvoh alone has to be large enough to justify that spend when Omvoh is already selling. The HS Phase 2 dataset (Forman JAAD 2026, NCT04493502) is the first standalone efficacy look at eltrekibart in a neutrophil-driven inflammatory disease [2][3], and because it missed the pre-specified primary comparison, it does not provide strong external validation to lean on ahead of the UC readout.

Our model estimates a 17% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 30%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by the sponsor's strong record of getting drugs approved and more secondary endpoints than usual; it is held back by weak or limited earlier-phase results and a randomized design. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk sits at the top, and the HS Phase 2 result reinforces it. On the pre-specified in-trial comparison (Forman JAAD 2026), eltrekibart delivered HiSCR50 in 48.9% of patients vs. 31.8% on placebo - a 17.1-point numerical advantage that fell short of statistical significance (p=0.19). The Bayesian augmented-control secondary analysis pooled the trial placebo arm with historical placebo controls, producing 65.6% vs. 32.3% and 99.9% posterior probability of superiority [3]. Regulators and payers weight pre-specified primary endpoints heavily and treat non-pre-specified augmented-control analyses as supportive at best, so this reads as a mixed signal, not the wide-margin win that would materially raise UC combination odds. Neutrophils are one arm of a complex immune cascade in UC. Suppressing them may improve histology without moving the endpoints that pay: clinical remission, endoscopic response, and durable steroid-free maintenance. Combination trials in immunology have a mixed record. Anti-TNF plus vedolizumab combinations and JAK-plus-biologic strategies have generally failed to beat well-selected monotherapy by enough to justify the added cost and safety burden. Safety risk is real. Neutrophils are the frontline defense against bacteria and fungi. CXCR2 small-molecule antagonists in COPD showed clinically meaningful neutropenia and infection signals. Eltrekibart neutralizes ligands rather than the receptor, which may soften the neutropenia signal (the HS trial reported mostly mild-to-moderate treatment-emergent AEs), but the multi-year infection risk in a chronic disease like UC will need long exposure data to characterize. Execution risk is low. Lilly runs IBD trials competently, has active Omvoh commercial infrastructure, and can pull enrollment through its existing investigator network. Commercial risk is the sneaky one. Even a positive combo readout has to beat Omvoh monotherapy by enough to justify pricing two biologics on top of each other. UC already has around 14 approved advanced therapies (anti-TNFs, anti-integrins, anti-IL-12/23, anti-IL-23p19, JAK inhibitors, S1P modulators). Anything short of transformative efficacy gets slotted into third- or fourth-line positioning, where the addressable patient population is smaller and payer management is heavier.

Worth watching, not urgent - and the near-term biology check has already partly arrived. The Forman JAAD 2026 HS paper missed its pre-specified primary comparison (HiSCR50, defined as a 50% reduction in the total count of abscesses and inflammatory nodules with no increase in draining fistulas - the standard efficacy bar in HS clinical trials) at p=0.19, with a 17.1-point numerical delta. The Bayesian augmented-control secondary showed 99.9% posterior superiority [3]. That is exactly the marginal signal that our own framework said would make the UC readout a longer shot. The mechanism is alive but not validated; there is no external tailwind for the UC combination hypothesis. The signal to track in NCT06598943 (primary completion December 2027): clinical remission rate in the combo arm relative to the mirikizumab-monotherapy comparator arm, plus endoscopic response. A 10-plus percentage point delta over mirikizumab alone justifies Phase 3. Anything less and Lilly probably repurposes the asset or shelves it. Commercial context: Eli Lilly booked roughly $65.2B in 2025 revenue, dominated by the tirzepatide franchise (Mounjaro and Zepbound) [7]. Omvoh (mirikizumab) is still a modest launch - Q4 2025 sales were $148M, up 30% year-over-year, implying full-year 2025 revenue in the roughly $290-300M range [7]. That is real but small next to the $10B+ franchises Skyrizi and Rinvoq that Omvoh is trying to displace in IBD. Eltrekibart's success or failure will not move Lilly. Its strategic value is as a portfolio option to defend Omvoh against Skyrizi and Rinvoq in IBD, and as a proof point for the anti-ELR+ chemokine mechanism that could later open up hidradenitis suppurativa or other neutrophil-driven diseases. Check back when NCT06598943 posts interim data, and watch for any Lilly commentary on whether the HS result is being treated as go/no-go for a Phase 3 HS program.